<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2026">
  <stage>Registered</stage>
  <submitdate>25/06/2008</submitdate>
  <approvaldate>25/06/2008</approvaldate>
  <nctid>NCT00707317</nctid>
  <trial_identification>
    <studytitle>T Cell Interferon-gamma Release Assay (TIGRA) in Immunocompromised Individuals</studytitle>
    <scientifictitle>Prospective Head-to-head Comparison of the Two Commercially Available Approved TIGRA (QuantiFERON-TB Gold In-Tube and T.SPOT.TB) With the Established Mendel-Mantoux Skin-test in Immunocompromized Patients</scientifictitle>
    <utrn />
    <trialacronym>TBNET-TIPS</trialacronym>
    <secondaryid>TBNET-TIGRA</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Tuberculosis</healthcondition>
    <healthcondition>Monitoring, Immunologic</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1 - HIV infected individuals

2 - patients with chronic renal failure

3 - patients after solid organ transplantation (lung, liver, kidney, kidney-pancreas)

4 - patients with rheumatoid arthritis

5 - stem cell transplant recipients

6 - immunocompromised patients with confirmed tuberculosis

7 - immunocompetent controls with no known risk of exposure or tuberculosis

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>IGRA performance - performance of two IGRAs and skin test in immunocompromised patients</outcome>
      <timepoint>at the time of analysis</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>active tuberculosis on follow-up - Active TB on follow-up depending on test result</outcome>
      <timepoint>variable follow-up on all patients</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Individual as specified for the study population

          -  Written informed consent

          -  Indication to perform tuberculin skin test(suspect latent infection, according to
             standard guidelines, differential diagnosis)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  &lt;18 years of age</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1843</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Cellestis Limited - Carnegie</hospital>
    <postcode> - Carnegie</postcode>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Herlev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Borstel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Homburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Mezourlo-Larissa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Tradate</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>The Hague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisbon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Tuberculosis Network European Trialsgroup</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Until recently, the tuberculin skin test (TST) was the only available diagnostic assay for
      detection of latent infection with M. tuberculosis (LTBI). Despite the low overall incidence
      of symptomatic tuberculosis infection in low-prevalence countries, the potential mortality
      and morbidity mandate constant vigilance to identify patients at risk for reactivation. Due
      to systemic immunosuppression, immunocompromised patients with latent M. tuberculosis
      infection are at increased risk of progression to active disease. This applies to patients
      with various causes of immunodeficiency such as HIV-infected patients, allogeneic stem cell
      and solid organ transplant recipients, patients with rheumatoid arthritis and patients with
      chronic renal failure. Therefore, current guidelines aimed at preventing tuberculosis
      infection in immunocompromized individuals recommend a generalized screening for evidence of
      latent infection to target appropriate preventative prophylaxis. At present, tuberculosis
      control programs exclusively rely on the tuberculin skin test to identify a latent infection
      in asymptomatic individuals.

      Recently, novel in vitro assays termed T cell interferon-gamma release assay (TIGRA) have
      become available that are based on the detection of interferon-gamma (IFN-gamma) production
      in T cells or supernatants after stimulation with highly specific antigens of M.
      tuberculosis. Two TIGRA are commercially available, the ELISPOT based T.SPOT.TB and the ELISA
      based QuantiFERON-TB Gold test (now available as an "IN-TUBE" version).

      The aim of the study is a prospective comparison of the two commercially available approved
      TIGRA (QuantiFERON-TB Gold In-Tube and T.SPOT.TB) with the established Mendel-Mantoux
      skin-test in immunocompromized patients (main focus on sensitivity and specificity).

      The study hypotheses are as follows:

        1. In immunocompromised patients, the two commercially available approved TIGRA
           (QuantiFERON-TB Gold In-Tube and T.SPOT.TB) have increased sensitivity and specificity
           as compared to the established Mendel-Mantoux skin-test.

        2. Results from QuantiFERON-TB Gold In-Tube and T.SPOT.TB do not differ in
           immunocompromised patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00707317</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Martina Sester, PhD</name>
      <address>Department of Transplant and Infection Immunology, University of the Saarland, 66421 Homburg</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>